A polygenic risk score may predict future breast cancer in patients with early-stage diagnoses
Bottom Line: In a retrospective study, the 313-SNP breast cancer polygenic risk score (PRS313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
Journal in Which the Study was Published: Cancer Epidemiology, Biomarker & Prevention, a journal of the American Association for Cancer Research (AACR)
Author: Jasmine Timbres, clinical information analyst at King’s College London and the study’s lead author, and Elinor J. Sawyer, PhD, the study’s senior author and professor of clinical oncology at King’s College London in the United Kingdom.
Background: ...